Journal article icon

Journal article

No evidence for spread of Plasmodium falciparum artemisinin resistance to Savannakhet Province, Southern Laos.

Abstract:
We conducted an open-label, randomized clinical trial to assess parasite clearance times (PCT) and the efficacy of 4 mg/kg (group 1, n = 22) and 2 mg/kg (group 2, n = 22) of oral artesunate for three days followed by artemether-lumefantrine in patients with uncomplicated Plasmodium falciparum malaria at Xepon Interdistrict Hospital, Savannakhet Province in southern Laos. Slides were read in duplicate. The overall mean (95% confidence interval; range) PCT in hours was 23.2 (21.2-25.3; 12-46) and 22.4 (20.3-24.5; 12-46) for the first and second microscopists, respectively (P = 0.57). Ten (23%) patients remained parasitemic on day 1 after treatment (4 [18%] in group 1 and 6 [27%] in group 2; P = 0.47). No patient had patent asexual parasitemia on the second and third days of treatment. The 42-day polymerase chain reaction-corrected cure rates were 100% in both treatment groups. Serious adverse events did not develop during or after treatment in any patients. In conclusion, no evidence of P. falciparum in vivo resistance to artesunate was found in southern Laos.
Publication status:
Published

Actions


Access Document


Publisher copy:
10.4269/ajtmh.2012.11-0497

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Role:
Author


Journal:
American journal of tropical medicine and hygiene More from this journal
Volume:
86
Issue:
3
Pages:
403-408
Publication date:
2012-03-01
DOI:
EISSN:
1476-1645
ISSN:
0002-9637


Language:
English
Keywords:
Pubs id:
pubs:316285
UUID:
uuid:3357b3b8-f20a-429a-95d4-59542f4aaa4c
Local pid:
pubs:316285
Source identifiers:
316285
Deposit date:
2012-12-19

Terms of use



Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP